Use of antifibrinolytic therapy in the perioperative period in children
Abstract
The course of surgical interventions in children can be complicated by the development of perioperative bleeding. The use of drugs with antifibrinolytic action reduces and prevents the development of intraoperative blood loss in adults and children. Antifibrinolytic drugs such as tranexamic acid have been shown to be effective in reducing perioperative blood loss, transfusion in adult patients and children in trauma, cardiosurgical and major orthopedic interventions. However, the use of this drug in the category of high-risk patients and in loading doses > 100 mg/kg may be associated with the development of thromboembolic and convulsive complications. One of the advantages of using aminocaproic acid is wide availability, cost and, at the same time, effectiveness. Comparing the effectiveness of lysine derivatives in patients with craniosynostosis, A.Borst and C. Bonfield note that when using aminocaproic acid compared to tranexamic acid, the level of intraoperative blood loss increases (21 ± 13 vs. 17 ± 10), but it is not statistically significant. Aprotinin, as a drug for reducing blood circulation in cardiosurgical diseases in comparison with lysine derivatives, is more effective for reducing perioperative blood. After The Blood Conservation Using Antifibrinolytics in a Randomized Trial (BART) (Fergusson D. et al. 2008) aprotinin is limited in many countries because of the high rate of thromboembolic complications and increased mortality. Currently, the anti-inflammatory properties of not only aprotinin, but also tranexamic and aminocaproic acids are being actively investigated.
References
Alshryda S., Sarda P., Sukeik M., et al. (2011) Tranexamic acid in total knee replacement: A sys- tematic review and meta-analysis. J Bone Joint Surg Br 93:1577–85. https://doi.org/10.1302/0301-620X.93B12.26989
Alshryda S., Sukeik M., Sarda P., et al. (2014) A systematic review and meta-analysis of the topi- cal administration of tranexamic acid in total hip and knee replacement. Bone Joint J 96-B:1005–15. https://doi.org/10.1302/0301-620X.96B8.33745
Anonymous. (2021) Patient Blood Managent Guidelines: Module 2 – Perioperative. Canberra, Australia: National Blood Authority P-53-60.
Australian Public Assessment Report for Tranexamic Acid. Australian Government. Department of Health and Aging. Therapeutic Goods Administration. December 2010. p3–137.
Bradfield J., Bode A. (2003) Aprotinin restores the adhesive capacity of dysfunctional platelets. Thromb. Res. 109, 181–188. https://doi.org/10.1016/s0049-3848(03)00182-8. PMID: 12757772.
Brown J., Andrew W.J., et al. (2009) Anti-Inflammatory Effect of Aprotinin: A Meta-Analysis The Journal of ExtraCorporeal Technology 41:79–86. PMCID: PMC4680210
Buerke M., Pruefer D., Sankat D. , et al. (2007) Effects of aprotinin on gene expression and protein synthesis after ischemia and reperfusion in rats Circulation 116(11 Suppl):I121-6. https://doi.org/10.1161/CIRCULATIONAHA.106.680249.
Chauhan S., Bisoi A., Kumar N., et al. (2004) Dose comparison of tranexamic acid in pediatric cardiac surgery. Asian Cardiovasc Thorac Ann 12:121 – 124. https://doi.org/10.1177/021849230401200208.
Day J., Taylor K., Lidington E., et al. (2006) Aprotinin inhibits proinflammatory activation of endothelial cells by thrombin through the protease-activated receptor 1. J Thorac Cardiovasc Surg 131(1):21-7. https://doi.org/10.1016/j.jtcvs.2005.08.050.
Fergusson D., Hébert P., Mazer C., et al. (2008)A comparison of aprotinin and lysine analogues in high-risk cardiac surgery (BART). N Engl J Med. 358(22):2319–31. https://doi.org/10.1056/NEJMoa0802395.
Florentino-Pineda I., Thompson G., Poe-Kochert C., et al. (2004). The effect of amicar on perioperative blood loss in idiopathicscoliosis: the results of a prospective, randomized double-blind study. Spine; 29: 233–8. https://doi.org/10.1097/01.brs.0000109883.18015.b9
Goobie S., Haas T. (2016). Perioperative bleeding management in pediatric patients. Curr Opin Anaesthesiol ; 29:352–358. https://doi.org/10.1097/ACO.0000000000000308
Goobie S., Meier P., Pereira L., et al. (2011) Efficacy of tranexamic acid in pediatric craniosynostosis surgery: a double-blind, placebo-controlled trial. Anesthesiology; 114:862 – 871. https://doi.org/10.1097/ALN.0b013e318210fd8f.
Henry D., Carless P., Moxey A., et al. (2007). Anti-fibrinolytic use for minimizing perioperative allogeneic blood transfusion. Cochrane Database of Systematic Reviews(4):CD001886.
Hsu G., Taylor J., Fiadjoe J., et al. (2016) Aminocaproic acid administration is associated with reduced perioperative blood loss and transfusion in pediatric craniofacial surgery. Acta Anaesthesiologica Scandinavica 60 158–165. https://doi.org/10.1111/aas.12608
Jansen N., Bollen C.. (2009) The effect of aprotinin, tranexamic acid, and aminocaproic acid on blood loss and use of blood products in major pediatric surgery: a meta-analysis. Pediatr Crit Care Med 2009; 10:182. https://doi.org/10.1097/PCC.0b013e3181956d61
Katzung B., Masters S., Trevor J., et al. Basic & Clinical Pharmacology 12th Edition Section 6, p- 616-617
Khan T., Bianchi C., Voisine P. et al.(2005). Aprotinin inhibits protease-dependent platelet aggregation and thrombosis. Ann. Thorac. Surg. 79, 1545–1550. https://doi.org/10.1016/j.athoracsur.2004.11.006
Kietaibl S., Ahmed A., Afshar A., et al. (2022) Management of severe perioperative bleeding: guidelines from the European Society of Anaesthesiology second update 2022. Eur J Anaesthesiol 2023; 40:226–304. https://doi.org/10.1097/EJA.0000000000001803
King M., Staffa S., Stricker P., et al. (2022) Safety of antifibrinolytics in 6583 pediatric patients having craniosynostosis surgery: A decade of data reported from the multicenter Pediatric Craniofacial Collaborative Group Vol 32, 12: 1339-1346. https://doi.org/10.1111/pan.14540
Kratzer S., Irl H., Mattusch C., et al.(2014) Tranexamic acid impairs gamma-aminobutyric acid receptor type A-mediated synaptic transmission in the murine amygdala: a potential mechanism for drug-induced seizures? Anesthesiology ; 120:639–649. https://doi.org/10.1097/aln.0000000000000103
Levy J. (2010). Antifibrinolytic therapy: new data and new concepts. Lancet; 376:3–4. https://doi.org/10.1016/S0140-6736(10)60939-7
Maniatis A., Earnshaw P., Benoni G., et al. (2011) Detection, evaluation, and management of preoperative anaemia in the elective orthopaedic surgical patient: NATA guideline. Br J Anaesth. Jan;106(1):13-22. https://doi.org/10.1093/bja/aeq361
Molenaar I., Warnaar N., Groen H., et al. (2007) Efficacy and safety of antifibrinolytic drugs in liver transplantation: A systematic review and meta-analysis. Am J Transplant 7:185–94. https://doi.org/10.1111/j.1600-6143.2006.01591.x
Nilsson I. (1980) Clinical pharmacology of aminocaproic and tranexamic acids. J Clin Pathol Suppl (R Coll Pathol) 14:41–47.
Ortmann E., Besser M., Klein A. (2013) Antifibrinolytic agents in current anaesthetic practice. Br J Anaesth ; 111:549–563. https://doi.org/10.1093/bja/aet154
Sharma V., Katznelson R., Jerath A.,et al. (2013) The association between tranexamic acid and convulsive seizures after cardiac surgery: a multivariate analysis in 11 529 patients. Anaesthesia; 69: 124–30. https://doi.org/10.1111/anae.12516
Sukeik M., Alshryda S., Haddad F., et al. (2011) Systematic review and meta-analysis of the use of tranexamic acid in total hip replacement. J Bone Joint Surg Br 93:39–46. https://doi.org/10.1302/0301-620X.93B1.24984
The CRASH -2 trial collaborators (2010) Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial. The Lancet Vol. 376 P-23-32. https://doi.org/10.1016/S0140- 6736(10)60835-5
The CRASH-3 trial collaborators (2019) Effects of tranexamic acid on death, disability, vascular occlusive events and other morbidities in patients with acute traumatic brain injury (CRASH-3): a randomised, placebo-controlled trial. The Lancet Vol.394 P1713-1723. https://doi.org/10.1016/S0140-6736(19)32233-0
Tzortzopoulou A., Cepeda M., Schumann R., et al.(2008) Antifibrinolytic agents for reducing blood loss in scoliosis surgery in children. Cochrane Database Syst Rev (3):CD006883.
This work is licensed under a Creative Commons Attribution 4.0 International License.
ISSN 
ISSN 
